Bayer Clears Two Legal Hurdles in a Single Week as Berenberg Lifts Its Target
Published on 11/21/2026 at 18:01 | Editorial boerse-global.deA Delaware court has closed the book on a challenge to Bayer's $2 billion acquisition of Vividion, while a Missouri judge has signed off on the company's sweeping Roundup settlement — twin rulings that remove uncertainty on two very different fronts.
Berenberg raised its price target on Bayer from EUR 53.50 to EUR 62.00 on Wednesday, keeping its rating at "Hold." The shares closed the previous session at EUR 55.16, still trading below the new target.
Delaware's top court on Thursday upheld the dismissal of a lawsuit brought by a Vividion investor over Bayer's $2 billion takeover of the company. The plaintiff, the court found, could not show that the release of intellectual property he objected to had influenced the purchase price.
Roundup: a cap, not a clean slate
The Missouri ruling, issued a day earlier, gives final approval to a nationwide Roundup settlement that lets Bayer pay up to $7.25 billion over as many as 21 years to resolve current and future US claims tied to non-Hodgkin lymphoma. Judge Timothy Boyer called the agreement "fair, reasonable and appropriate" and, according to Reuters, rejected objections to the size of the compensation.
Should investors sell immediately? Or is it worth buying Bayer?
Chief executive Bill Anderson described the approval as a milestone. The company stressed it does not constitute an admission of liability. Monsanto is to pay the money into a fund over up to 21 years, with sums already disbursed counted toward the ceiling.
The settlement covers people who developed non-Hodgkin lymphoma after exposure to Roundup, or who may yet do so, provided the contact occurred before February 17. Diagnosed illnesses qualify, as do diagnoses made within 16 years of the agreement taking effect. Deutsche Welle puts expected individual payouts at $10,000 to $165,000, with the figure depending on the claimant's age, the severity of the illness and the length of exposure.
What the deal leaves exposed
Roughly 200 cases still pending in US federal courts sit outside the settlement, meaning the cap applies to the fund rather than to every legal risk stemming from glyphosate. Bayer did win a favorable ruling from the US Supreme Court in June, which narrowed claims alleging a failure to warn of cancer risks on product packaging. The settlement addresses a different question — compensation for claimed illnesses, including future diagnoses under certain conditions — and so gives the company a defined payment envelope for a large share of the claims.
Appeals against the approval remain possible. If they are filed, payments would be paused until the appellate proceedings conclude, so the timing of outflows, not just the headline figure, is what investors will be watching.
Bayer at a turning point? This analysis reveals what investors need to know now.
Ethiopia and the analyst view
Separately, Bayer and Ethiopian agricultural technology firm Lersha agreed a partnership on November 12 aimed at giving nearly 750,000 farming households access to inputs, financing, advice and sales markets. A possible seed-processing plant in Ethiopia remains subject to an investment decision.
Against that operational backdrop, Berenberg's move leaves the stock trading below its revised target — a signal that the legal clarity is being weighed alongside the company's broader outlook rather than treated as a re-rating trigger on its own.
Ad
Bayer Stock: New Analysis - 21 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
